Skip to main content
SpringerLink
Log in

Modern Anti-Tuberculosis Drugs and Their Classification. Part I: First-Line Drugs

  • SEARCH FOR NEW DRUGS
  • Published:
Pharmaceutical Chemistry Journal Aims and scope

The historical classification (1993) of anti-tuberculosis drugs included three (I-III) lines that were subdivided into five groups (2006). The duration of treatment of drug-sensitive (DS) tuberculosis (TB) with first-line drugs is 6 – 12 months; of multidrug-resistant (MDR) TB and extensively drug-resistant (XDR) TB with second-line drugs, 18 months and longer. The Directly Observed Treatment Short course (DOTS) and DOTS-Plus therapies are measures of world TB control. Based on the need for more effective treatment of MDR and XDR TB, the classification of 2016 introduced six groups (A-C and D1-D3) in connection with the development of new anti-TB drugs. The present review presents first-line preparations and their new derivatives possessing activity against DS and drug-resistant (DR) M. tuberculosis strains.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

Notes

  1. Efflux pump resistance mechanisms are responsible for transport of compounds such as neurotransmitters, toxic substances, and antibiotics from cells. This mechanism is important because it enhances MTB resistance to bacterial antibiotics. Efflux pump systems function by removing undesired toxic substances through special efflux pumps. Several efflux systems creating a barrier to drug penetration into the bacterial cell are specific for drugs while others can facilitate penetration of various drugs into bacterial cells, creating only slight multidrug resistance.

References

  1. Treatment of TB: Guidelines for National Programmes. World Health Organization, WHO/TB/97.220, 1997.

  2. World Health Organization. The treatment of tuberculosis guidelines. Document WHO/HTM/TB/2009.420, WHO, Geneva, 2010.

  3. WHO consolidated guidelines on drug-resistant tuberculosis treatment, World Health Organization, Geneva, 2019; Licence: CC BY-NC-SA 3.0 IGO.

  4. Fact Sheets Elimination Tuberculosis: General Information. October 2011; https://www.cdc.gov/tb/publications/factsheets/general/tb.htm.

  5. R. Bayer and D. Wilkinson, Lancet, 345(8964), 1545 – 1548 (1995).

    CAS  PubMed  Google Scholar 

  6. J. M. Grange, Int. J. Tuberc. Lung Dis., 1(4), 293 – 296 (1997).

    CAS  PubMed  Google Scholar 

  7. World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis: www.who.int/tb/challenges/mdr/programmatic_guidelines_for_mdrtb/en/; Date last accessed: Dec. 12, 2012. Date last updated: 2011.

  8. World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis. WHO/HTM/TB/2006.361, World Health Organization, Geneva, 2006.

  9. World Health Organization. Companion handbook to the WHO guidelines for the programmatic management of drug-resistant tuberculosis. WHO/HTM/TB/2014.11, World Health Organization, Geneva, 2014.

  10. World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis. Emergency update 2008. WHO/HTM/TB/2008.402, World Health Organization, Geneva, 2008.

  11. The use of bedaquiline in the treatment of multidrug-resistant tuberculosis. Interim policy guidance. World Health Organization, 2013.

  12. World Health Organization. The use of delamanid in the treatment of multidrug-resistant tuberculosis. Interim policy guidance, 2014.

  13. A. Rendon, S. Tiberi, A. Scardigli, et al., J. Thorac. Dis., 8(10), 2666 – 2671 (2016).

    PubMed  PubMed Central  Google Scholar 

  14. E. Jaramillo, SESSION 5, Jun. 1, 2017. New and repurposed anti-TB drug introduction. WHO policies related with management of drug-resistant tuberculosis. Global TB Programme, WHO/HQ/LDR unit, Geneva, 2017.

  15. P. Purkan, I. Ihsanawati, D. Natalia, et al., Ukr. Biochem. J., 88(5), 71 – 81 (2016).

    CAS  PubMed  Google Scholar 

  16. Y.-Q. Hu, S. Zhang, F. Zhao, et al., Eur. J. Med. Chem., 133, 255 – 267 (2017).

    CAS  PubMed  Google Scholar 

  17. R. Tandon and M. Nath, Mini-Rev. Med. Chem., 17(6), 549 – 570 (2017).

    CAS  PubMed  Google Scholar 

  18. Z. Rychtarcikova, M. Kratky,M. Gazdova, et al., Molecules, 19, 3851 – 3868 (2014).

    PubMed  PubMed Central  Google Scholar 

  19. M. O. Rodrigues, J. B. Cantos, C. R. M. D’Oca, et al., Bioorg. Med. Chem., 21(22), 6910 – 6914 (2013).

    CAS  PubMed  Google Scholar 

  20. D. K. Beena, G. Khare, S. Kidwai, et al., Eur. J. Med. Chem., 81, 301 – 313 (2014).

    PubMed  Google Scholar 

  21. J. P. Raval, N. H. Patel, H. V. Patel, et al., Chem. Res., 20, 274 – 279 (2011).

    CAS  Google Scholar 

  22. G. F. dos S. Fernandes, P. S. de Souza, L. B. Marino, et al., Eur. J. Med. Chem., 123, 523 – 531 (2016).

  23. G. F. dos S. Fernandes, P. C. de Souza, E. Moreno-Viguri, et al., J. Med. Chem., 60(20), 8647 – 8660 (2017).

  24. H. S. N. Kumar, T. Paramasivam, F. Jumaat, et al., Med. Chem. Res., 23, 269 – 279 (2014).

    Google Scholar 

  25. P. Kumar, P. Rawat, P. Singh, et al., Int. J. Pharm. Sci. Res., 4(6), 2080 – 2093 (2013).

    CAS  Google Scholar 

  26. N. Anand, K. Upadhyaya, and R. P. Tripathi, Chem. Biol. Interface, 5(2), 84 – 127 (2015).

    CAS  Google Scholar 

  27. B. Prideaux, L. E. Via, M. D. Zimmerman, et al., Nat. Med., 21, 1223 – 1227 (2015).

    CAS  PubMed  PubMed Central  Google Scholar 

  28. W. Manosuthi, S. Wiboonchutikul, and S. Sungkanuparph, AIDS Res. Ther., 13, 22 (2016).

    PubMed  PubMed Central  Google Scholar 

  29. M. Asif, World J. Org. Chem., 1, 14 – 19 (2013).

    Google Scholar 

  30. A. N. Unissa, L. E. Hanna, and S. Swaminathan, Chem. Biol. Drug Des., 87, 537 – 550 (2016).

    Google Scholar 

  31. T. Rawal and S. Butani, Indian J. Pharm. Sci., 78(1), 8 – 16 (2016).

    CAS  PubMed  PubMed Central  Google Scholar 

  32. “Adis Insight: Rifalazil (ABI 1648; KRM 1648; PA 1648)”, Adis Insight, Springer International Publishing AG, 2016.

  33. K. E. Dooley, C. D. Mitnick, M. A. DeGroote, et al., Clin. Infect. Dis., 55(4), 572 – 581 (2012).

    PubMed  PubMed Central  Google Scholar 

  34. K.-W. Jo, W. Ji, Y. Hong, et al., Respir. Med., 107, 292 – 297 (2013).

    PubMed  Google Scholar 

  35. K. E. Dooley, P. Sayre, J. Borland, et al., J. Acquired Immune Defic. Syndr., 62(1), 21 – 27 (2013).

    CAS  Google Scholar 

  36. T. R. Sterling, N. A. Scott, J. M. Miro, et al., AIDS (London, U. K.), 30(10), 1607 – 1615 (2016).

  37. A. Jindani, T. S. Harrison, A. J. Nunn, et al., N. Engl. J. Med., 371(17), 1599 – 1608 (2014).

    PubMed  PubMed Central  Google Scholar 

  38. Treatment of Tuberculosis, Guidelines for treatment of drug-susceptible tuberculosis and patient care, 2017 UPDATE, World Health Organization, 2017.

  39. 1 Month of TB prophylaxis as effective as 9 months, Infectious Disease. Respiratory Infect. Dis. News, Healio, 2018.

  40. M. Njire, Y. Tan, J. Mugweru, et al., Adv. Med. Sci., 61(1), 63 – 71 (2016).

    PubMed  Google Scholar 

  41. S. Sarkar, A. Ganguly, and H. H. Sunwoo, Mycobact. Dis., 6, 209 (2016).

    Google Scholar 

  42. Y. S. Kwon, Chonnam Med. J., 53(2), 103 – 109 (2017).

    CAS  PubMed  PubMed Central  Google Scholar 

  43. Z. Ahmad, S. Tyagi, A. Minkowski, et al., Indian J. Med. Res., 136(5), 808 – 814 (2012).

    CAS  PubMed  PubMed Central  Google Scholar 

  44. J. Zitko, B. Servusova, P. Paterova, et al., Molecules, 18(12), 14807 – 14825 (2013).

    CAS  PubMed  PubMed Central  Google Scholar 

  45. O. Jandourek, M. Tauchman, P. Paterova, et al., Molecules, 22, 223 – 243 (2017).

    PubMed Central  Google Scholar 

  46. S. Zhou, S. Yang, and G. Huang, J. Enzyme Inhib. Med. Chem., 32(1), 1183 – 1186 (2017).

    CAS  PubMed  PubMed Central  Google Scholar 

  47. N. D. Segretti, C. K. Simoes, M. F. Correa, et al., Tuberculosis, 99, 11e16 (2016).

    Google Scholar 

  48. M. F. Correa and J. P. S. Fernandes, Curr. Protein Pept. Sci., 17(3), 213 – 219 (2016).

    CAS  PubMed  Google Scholar 

  49. G. B. Migliori and A. Zumla, in: Infectious Diseases, 4th Ed., J. Cohen, W. G. Powderly, and S. M. Opal (eds.), Elsevier, Amsterdam, 2017, pp. 1264 – 1276.e2.

  50. K. Kumar and A. V. Narsaiah, Org. Commun., 7(1), 28 – 33 (2014).

    Google Scholar 

  51. M. Asif, Elixir. Farmacy, 53, 11774 – 11778 (2012).

    Google Scholar 

  52. H. Safi, S. Lingaraju, A. Amin, et al., Nat. Genet., 45, 1190 – 1197 (2013).

    CAS  PubMed  PubMed Central  Google Scholar 

  53. K. Schubert, B. Sieger, F. Meyer, et al., mBio, 8(1), e02213 – 16 (2017).

  54. R. E. Lee, M. Protopopova, E. Crooks, et al., J. Comb. Chem., 5(2), 172 – 187 (2003).

    CAS  PubMed  Google Scholar 

  55. M. N. Protopopova, in: Advances in Tuberculosis Medicinal Chemistry, M. Kuroso and W. Denny (eds.), Future Science Ltd. — Unitec House, London (2016), Chap. 7, pp. 104 – 118.

  56. D. Machado, M. Girardini, M. Viveiros, and M. Pieroni, Front Microbiol., 9, 1367 (2018).

    PubMed  PubMed Central  Google Scholar 

  57. O. K. Onajole, P. Govender, and P. D. van Helden, Eur. J. Med. Chem., 45, 2075 – 2079 (2010).

    CAS  PubMed  Google Scholar 

  58. S. E. Borisov, E. M. Bogorodskaya, G. V. Volchenkov, et al., Tuber. Lung Dis., 96(3), 6 – 18 (2018).

    Google Scholar 

  59. M. J. Boeree, N. Heinrich, R. Aarnoutse, et al., Lancet Infect. Dis., 17(1), 39 – 49 (2017).

    CAS  PubMed  PubMed Central  Google Scholar 

  60. B. P. Goldstein, J. Antibiot., 67(9), 625 – 630 (2014).

    CAS  PubMed  Google Scholar 

  61. C. Vilcheze, Jr., and W. Jacobs, Microbiol. Spectrum, 2(4), MGM2 – 0014 – 2013 (2014).

  62. Y. Zhang, W. Shi, W. Zhang, and D. Mitchison, Microbiol. Spectrum, 2(4), 1 – 12 (2014).

    Google Scholar 

  63. N. Dookie, S. Rambaran, N. Padayatchi, et al., J. Antimicrob. Chemother., 73, 1138 – 1151 (2018).

    CAS  PubMed  PubMed Central  Google Scholar 

  64. J. Bacon, L. J. Alderwick, J. A. Allnutt, et al., PLoS One, 9(2), e87329 (2014).

    PubMed  PubMed Central  Google Scholar 

  65. J. A. Caminero (ed.), Guidelines for Clinical and Operational Management of Drug-Resistant Tuberculosis, International Union Against Tuberculosis and Lung Disease, Paris, France, 2013.

  66. D. Falzon, F. Mirzayev, F. Wares, et al., Eur. Respir. J., 45, 150 – 160 (2015).

    PubMed  Google Scholar 

  67. D. C. Bay and R. J. Turner, Small Multidrug Resistance Efflux Pumps, Springer International Publishing, Switzerland, 2016, pp. 45 – 71.

    Google Scholar 

  68. J. Sun, Z. Deng, and A. Yan, Biochem. Biophys. Res. Commun., 453(2), 254 – 267 (2014).

    CAS  PubMed  Google Scholar 

  69. Y. Xu, J. Wu, S. Liao, et al., Ann. Clin. Microbiol. Antimicrob., 16(1), 1 – 13 (2017).

    Google Scholar 

  70. World Health Organization. Companion handbook to the WHO guidelines for the programmatic management of drug-resistant tuberculosis. World Health Organization. WHO/HTM/TB/2014.11, Geneva, 2014.

  71. D. Falzon, H. J. Schunemann, E. Harausz, et al., World Health Organization treatment guidelines for drug-resistant tuberculosis, 2016 update, Eur. Respir. J., 49(3), 1602308 (2017).

    PubMed  PubMed Central  Google Scholar 

  72. T. H. Keller, A. Pichota, and Z. Yin, Curr. Opin. Chem. Biol., 10, 357 – 361 (2006).

    CAS  PubMed  Google Scholar 

  73. G. Piccaro, G. Poce, M. Biava, et al., J. Antibiot., 68, 711 – 714 (2015).

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. A. B. Bekturov Institute of Chemical Sciences, Almaty, Kazakhstan

    L. A. Kayukova

  2. National Scientific Center of Phthisiopulmonology, Ministry of Health of the Republic of Kazakhstan, Almaty, Kazakhstan

    E. A. Berikova

Authors
  1. L. A. Kayukova
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. E. A. Berikova
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to L. A. Kayukova.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kayukova, L.A., Berikova, E.A. Modern Anti-Tuberculosis Drugs and Their Classification. Part I: First-Line Drugs. Pharm Chem J 54, 555–563 (2020). https://doi.org/10.1007/s11094-020-02239-2

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11094-020-02239-2

Keywords

Search

Navigation